We were stimulated to do this by the clear evidence that the distribution of pathogenic mutations in amyloid precursor protein (APP) and presenilin in Alzheimer's disease gives insight into their mode of pathogenicity [24,25]. This evidence concerns the gene APP and Alzheimer disease.